Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13,622 Mln
Revenue (TTM)
$718 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
14.6
Industry P/E
--
EV/EBITDA
-20.7
Div. Yield
0 %
Debt to Equity
-5.4
Book Value
$--
EPS
$-3.6
Face value
--
Shares outstanding
61,393,156
CFO
€-2,184.14 Mln
EBITDA
€-2,320.00 Mln
Net Profit
€-2,450.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
| 1.7 | -5.3 | 3.8 | 37.1 | 27.4 | 10.6 | 28.6 |
|
BSE Sensex
| -13.1 | -10.5 | -13.5 | -4.8 | 8.6 | 8.5 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
| 54.9 | 9.2 | 3.1 | -9.2 | -19.3 | 19.9 | 122.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients... with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Read more
President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
President, CEO, Member of Executive Board & Executive Director
Mr. Jan Moller Mikkelsen
Headquarters
Hellerup
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ascendis Pharma A/S - ADR is $216.95 (NASDAQ) as of 27-Mar-2026 16:00 EDT. Ascendis Pharma A/S - ADR has given a return of 27.41% in the last 3 years.
Since, TTM earnings of Ascendis Pharma A/S - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-59.76
|
-80.42
|
|
2024
|
-21.77
|
-77.86
|
|
2023
|
-14.81
|
-48.94
|
|
2022
|
-11.73
|
25.97
|
|
2021
|
-18.89
|
8.20
|
The 52-week high and low of Ascendis Pharma A/S - ADR are Rs 248.58 and Rs 124.06 as of 29-Mar-2026.
Ascendis Pharma A/S - ADR has a market capitalisation of $ 13,622 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ascendis Pharma A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-3.65
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.